Granted Patent B2

US 12,312,410 · App. 17/283,553 · Granted May 27, 2025

Inventors: Yangsheng Qiu (Shanghai, CN); Meiling Sun (Shanghai, CN); Roumei Xing (Shanghai, CN); Dan Xu (Shanghai, CN); Yufei Shi (Shanghai, CN); Jinfeng Zhao (Shanghai, CN); Qinglin Du (Shanghai, CN); Zhihao Wu (Shanghai, CN); Rui Gao (Shanghai, CN); Robert H. Arch (Shanghai, CN); Hongtao Lu (Shanghai, CN)

Assignee: ELPISCIENCE (SUZHOU) BIOPHARMA, LTD

C07K16/2896A61K39/3955A61P35/00A61K2039/505C07K2317/24C07K2317/565C07K2317/567C07K2317/76C07K2317/92

Abstract

Claims (80)

1. An antibody or an antigen-binding fragment thereof capable of specifically binding to human CD39, comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising LCDR1, LCDR2 and LCDR3, wherein

a) the HCDR1 comprises the amino acid sequence of DTFLH (SEQ ID NO: 4); and

b) the HCDR2 comprises the amino acid sequence of X 58 IDPAX 59 X 60 NIKYDPKFQG (SEQ ID NO: 151); and

c) the HCDR3 comprises the amino acid sequence of SPYYYGSGYRIFDV (SEQ ID NO: 16); and

d) the LCDR1 comprises the amino acid sequence of SAFSSVNYMH (SEQ ID NO: 22); and

e) the LCDR2 comprises the amino acid sequence of TTSNLAS (SEQ ID NO: 28); and

f) the LCDR3 comprises the amino acid sequence of QQRSTYPFT (SEQ ID NO: 34);

wherein X 58 is R or K, X 59 is N, G, S or Q, X 60 is G, A or D.

2. The antibody or an antigen-binding fragment thereof of claim 1 , wherein:

a) the HCDR1 comprises the sequence of SEQ ID NO: 4, the HCDR2 comprises the sequence of SEQ ID NO: 10, the HCDR3 comprises the sequence of SEQ ID NO: 16; the LCDR1 comprises the sequence of SEQ ID NO: 22, the LCDR2 comprises the sequence of SEQ ID NO: 28, and the LCDR3 comprises the sequence of SEQ ID NO: 34; or

b) the HCDR1 comprises the sequence of SEQ ID NO: 4, the HCDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 136, 137, 138, and 139, the HCDR3 comprises the sequence of SEQ ID NO: 16; the LCDR1 comprises the sequence of SEQ ID NO: 22, the LCDR2 comprises the sequence of SEQ ID NO: 28, and the LCDR3 comprises the sequence of SEQ ID NO: 34.

3. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising one or more of heavy chain HFR1, HFR2, HFR3 and HFR4, and/or one or more of light chain LFR1, LFR2, LFR3 and LFR4, wherein:

a) the HFR1 comprises the sequence of X 19 VQLVX 20 SGX 21 X 22 X 23 X 24 KPGX 25 SX 26 X 27 X 28 SCX 29 ASGX 30 X 31 X 32 X 33 (SEQ ID NO: 76) or a homologous sequence of at least 80% sequence identity thereof,

b) the HFR2 comprises the sequence of WVX 34 QX 35 PGX 36 X 37 LEWX 38 X 39 (SEQ ID NO: 77) or a homologous sequence of at least 80% sequence identity thereof,

c) the HFR3 sequence comprises the sequence of X 40 X 41 TX 42 X 43 X 44 DX 45 SX 46 X 47 TX 48 YX 49 X 50 X 51 X 52 SLX 53 X 54 EDTAVYYCX 55 X 56 (SEQ ID NO: 78) or a homologous sequence of at least 80% sequence identity thereof,

d) the HFR4 comprises the sequence of WGQGTX 57 VTVSS (SEQ ID NO: 126) or a homologous sequence of at least 80% sequence identity thereof,

e) the LFR1 comprises the sequence of X 3 IVX 4 TQSPATLX 5 X 6 SPGERX 7 TX 8 X 9 C (SEQ ID NO: 80) or a homologous sequence of at least 80% sequence identity thereof,

f) the LFR2 comprises the sequence of WYQQKPGQX 10 PX 11 LLIY (SEQ ID NO: 81) or a homologous sequence of at least 80% sequence identity thereof,

g) the LFR3 comprises the sequence of GX 12 PX 13 RFSGSGSGTX 14 X 15 TLTISSX 16 EPEDFAVYX 17 C (SEQ ID NO: 82) or a homologous sequence of at least 80% sequence identity thereof, and

h) the LFR4 comprises the sequence of FGX 18 GTKLEIK (SEQ ID NO: 152) or a homologous sequence of at least 80% sequence identity thereof,

wherein X 3 is E or Q; X 4 is L or M; X 5 is S or T; X 6 is L, V or A; X 7 is A or V; X 8 is L or I; X 9 is S or T; X 10 is A or S; X 11 is R or K; X 12 is I or V;

X 13 is A or T; X 14 is D or S; X 15 is F or Y; X 16 is L, M or V; X 17 is Y or F; X 18 is G or Q; X 19 is Q or E; X 20 is E or Q; X 21 is G or A; X 22 is G or E; X 23 is L or V; X 24 is V or K; X 25 is G or A; X 26 is L, M or V; X 27 is R or K; X 28 is V or L; X 29 is A or K; X 30 is F or Y; X 31 is N or T; X 32 is F or L; X 33 is S or K; X 34 is R or K; X 35 is A or S; X 36 is K or Q; X 37 is R or G; X 38 is M, I or V; X 39 is G or A; X 40 is R or K; X 41 is V, A or F; X 42 is I or L; X 43 is S or T; X 44 is R or A; X 45 is D or T; X 46 is K, A or S; X 47 is S or N; X 48 is L, V or A; X 49 is M or L; X 50 is Q or E; X 51 is M or L; X 52 is S, I or N; X 53 is R or K; X 54 is S or T; X 55 is A or T; X 56 is R, N or T; and X 57 is T or L.

4. The antibody or an antigen-binding fragment thereof of claim 1 , comprising a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 47, 60, 62, 64, 66, 68, 70, 72, 74, 140, 141, 142, 146, 147, 39, and a homologous sequence thereof having at least 80% sequence identity yet retaining specific binding affinity to human CD39, and

a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 56, 61, 63, 65, 67, 69, 71, 73, 75, 143, 144, 145, 111, 112, 63, and a homologous sequence thereof having at least 80% sequence identity yet retaining specific binding affinity to human CD39.

5. The antibody or an antigen-binding fragment thereof of claim 1 , comprising:

a) a heavy chain variable region comprising the sequence of SEQ ID NO: 47 and a light chain variable region comprising the sequence of SEQ ID NO: 56; or

b) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 63, or

c) a heavy chain variable region comprising the sequence of SEQ ID NO: 62 and a light chain variable region comprising the sequence of SEQ ID NO: 63, or

d) a heavy chain variable region comprising the sequence of SEQ ID NO: 64 and a light chain variable region comprising the sequence of SEQ ID NO: 63, or

e) a heavy chain variable region comprising the sequence of SEQ ID NO: 66 and a light chain variable region comprising the sequence of SEQ ID NO: 63, or

f) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 65, or

g) a heavy chain variable region comprising the sequence of SEQ ID NO: 62 and a light chain variable region comprising the sequence of SEQ ID NO: 65, or

h) a heavy chain variable region comprising the sequence of SEQ ID NO: 64 and a light chain variable region comprising the sequence of SEQ ID NO: 65, or

i) a heavy chain variable region comprising the sequence of SEQ ID NO: 66 and a light chain variable region comprising the sequence of SEQ ID NO: 65, or

j) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 67, or

k) a heavy chain variable region comprising the sequence of SEQ ID NO: 62 and a light chain variable region comprising the sequence of SEQ ID NO: 67, or

l) a heavy chain variable region comprising the sequence of SEQ ID NO: 64 and a light chain variable region comprising the sequence of SEQ ID NO: 67, or

m) a heavy chain variable region comprising the sequence of SEQ ID NO: 66 and a light chain variable region comprising the sequence of SEQ ID NO: 67, or

n) a heavy chain variable region comprising the sequence of SEQ ID NO: 140 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

o) a heavy chain variable region comprising the sequence of SEQ ID NO: 141 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

p) a heavy chain variable region comprising the sequence of SEQ ID NO: 142 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

q) a heavy chain variable region comprising the sequence of SEQ ID NO: 140 and a light chain variable region comprising the sequence of SEQ ID NO: 143, or

r) a heavy chain variable region comprising the sequence of SEQ ID NO: 141 and a light chain variable region comprising the sequence of SEQ ID NO: 143, or

s) a heavy chain variable region comprising the sequence of SEQ ID NO: 142 and a light chain variable region comprising the sequence of SEQ ID NO: 143, or

t) a heavy chain variable region comprising the sequence of SEQ ID NO: 140 and a light chain variable region comprising the sequence of SEQ ID NO: 144, or

u) a heavy chain variable region comprising the sequence of SEQ ID NO: 141 and a light chain variable region comprising the sequence of SEQ ID NO: 144, or

v) a heavy chain variable region comprising the sequence of SEQ ID NO: 142 and a light chain variable region comprising the sequence of SEQ ID NO: 144, or

w) a heavy chain variable region comprising the sequence of SEQ ID NO: 140 and a light chain variable region comprising the sequence of SEQ ID NO: 145, or

x) a heavy chain variable region comprising the sequence of SEQ ID NO: 141 and a light chain variable region comprising the sequence of SEQ ID NO: 145, or

y) a heavy chain variable region comprising the sequence of SEQ ID NO: 142 and a light chain variable region comprising the sequence of SEQ ID NO: 145, or

z) a heavy chain variable region comprising the sequence of SEQ ID NO: 146 and a light chain variable region comprising the sequence of SEQ ID NO: 111, or

aa) a heavy chain variable region comprising the sequence of SEQ ID NO: 146 and a light chain variable region comprising the sequence of SEQ ID NO: 112, or

bb) a heavy chain variable region comprising the sequence of SEQ ID NO: 147 and a light chain variable region comprising the sequence of SEQ ID NO: 111, or

cc) a heavy chain variable region comprising the sequence of SEQ ID NO: 39 and a light chain variable region comprising the sequence of SEQ ID NO: 63, or

dd) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

ee) a heavy chain variable region comprising the sequence of SEQ ID NO: 62 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

ff) a heavy chain variable region comprising the sequence of SEQ ID NO: 64 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

gg) a heavy chain variable region comprising the sequence of SEQ ID NO: 66 and a light chain variable region comprising the sequence of SEQ ID NO: 61, or

hh) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 143, or

ii) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 144, or

jj) a heavy chain variable region comprising the sequence of SEQ ID NO: 60 and a light chain variable region comprising the sequence of SEQ ID NO: 145.

6. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising one or more amino acid residue substitutions or modifications yet retains specific binding affinity to human CD39, wherein the one or more amino acid residue substitutions or modifications is within one or more of the non-CDR sequences of the heavy chain variable region or light chain variable region.

7. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising an Fc region.

8. The antibody or an antigen-binding fragment thereof of claim 1 , which is humanized.

9. The antibody or an antigen-binding fragment thereof of claim 1 , which is a monoclonal antibody, a bispecific antibody, a multi-specific antibody, a recombinant antibody, a chimeric antibody, a labeled antibody, a bivalent antibody, an anti-idiotypic antibody or a fusion protein.

10. The antibody or an antigen-binding fragment thereof of claim 1 , which is a diabody, a Fab, a Fab′, a F(ab′) 2 , a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv) 2 , a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), an scFv dimer (bivalent diabody), a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, or a bivalent domain antibody.

11. The antibody or an antigen-binding fragment thereof of claim 1 , which specifically binds to an epitope of CD39, wherein the epitope comprises one or more residues selected from the group consisting of Q96, N99, E143, R147, R138, M139, E142, K5, E100, D107, V81, E82, R111, and V115.

12. The antibody or an antigen-binding fragment thereof of claim 1 , which is linked to one or more conjugate moieties.

13. A composition comprising the antibody or an antigen-binding fragment thereof of claim 1 , and one or more pharmaceutically acceptable carriers.

14. An isolated polynucleotide encoding the antibody or an antigen-binding fragment thereof of claim 1 .

15. A vector comprising the isolated polynucleotide of claim 14 .

16. A host cell comprising the vector of claim 15 .

17. A kit comprising the antibody or an antigen-binding fragment thereof of claim 1 and/or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof and one or more pharmaceutically acceptable carriers, and a second therapeutic agent.

18. A method of expressing the antibody or antigen-binding fragment thereof of claim 1 , comprising culturing the host cell comprising a vector comprising an isolated polynucleotide encoding the antibody or antigen-binding fragment thereof under the condition at which the vector is expressed.

19. A method of modulating CD39 activity in a CD39-positive cell, comprising exposing the CD39-positive cell to the antibody or antigen-binding fragment thereof of claim 1 and/or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof and one or more pharmaceutically acceptable carriers.

20. A method of detecting the presence or amount of CD39 in a sample, comprising contacting the sample with the antibody or an antigen-binding fragment thereof of claim 1 and/or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof and one or more pharmaceutically acceptable carriers, and determining the presence or the amount of CD39 in the sample.

21. A kit comprising the antibody or an antigen-binding fragment thereof of claim 1 and/or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof and one or more pharmaceutically acceptable carriers, useful in detecting CD39.

22. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising an Fc region of human immunoglobulin (Ig).

23. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising an Fc region derived from human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2 or IgM.

24. The antibody or an antigen-binding fragment thereof of claim 1 , further comprising an Fc region derived from human IgG1 comprising a L234A and L235A mutation.

Assignments (2)

Priority Claims (2)

Continuity (1)

References Cited (31)